(NASDAQ: DRRX) Durect's forecast annual revenue growth rate of 297.85% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.24%.
Durect's revenue in 2025 is $525,000.On average, 1 Wall Street analysts forecast DRRX's revenue for 2025 to be $36,940,671, with the lowest DRRX revenue forecast at $36,940,671, and the highest DRRX revenue forecast at $36,940,671. On average, 1 Wall Street analysts forecast DRRX's revenue for 2026 to be $31,042,581, with the lowest DRRX revenue forecast at $31,042,581, and the highest DRRX revenue forecast at $31,042,581.
In 2027, DRRX is forecast to generate $1,226,492,375 in revenue, with the lowest revenue forecast at $1,226,492,375 and the highest revenue forecast at $1,226,492,375.